Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease |
Choi, Joo-Hyung
(Animal and Plant Quarantine Agency)
Jeong, Kwiwan (Bio-Center, Gyeonggi Business & Science Accelerator) Kim, Su-Mi (Animal and Plant Quarantine Agency) Ko, Mi-Kyeong (Animal and Plant Quarantine Agency) You, Su-Hwa (Animal and Plant Quarantine Agency) Lyoo, Young S. (College of Veterinary Medicine, Konkuk University) Kim, Byounghan (Animal and Plant Quarantine Agency) Ku, Jin-Mo (Bio-Center, Gyeonggi Business & Science Accelerator) Park, Jong-Hyeon (Animal and Plant Quarantine Agency) |
1 | Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, Lu Y, Zheng Z. Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo. J Virol 2006, 80, 3559-3566. DOI |
2 | Chinsangaram J, Moraes MP, Koster M, Grubman MJ. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 2003, 77, 1621-1625. DOI |
3 | Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993, 37, 532-539. DOI |
4 | de Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, Grubman MJ. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24, 3446-3456. DOI |
5 | Durk RC, Singh K, Cornelison CA, Rai DK, Matzek KB, Leslie MD, Schafer E, Marchand B, Adedeji A, Michailidis E, Dorst CA, Moran J, Pautler C, Rodriguez LL, McIntosh MA, Rieder E, Sarafianos SG. Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. PLoS One 2010, 5, e15049. DOI |
6 | Golde WT, Pacheco JM, Duque H, Doel T, Penfold B, Ferman GS, Gregg DR, Rodriguez LL. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 2005, 23, 5775-5782. DOI |
7 | Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M; International Pediatric Hepatitis C Therapy Group. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005, 42, 1010-1018. DOI |
8 | Kamstrup S, Frimann TH, Barfoed AM. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res 2006, 72, 42-48. DOI |
9 | Kim SM, Kim SK, Park JH, Lee KN, Ko YJ, Lee HS, Seo MG, Shin YK, Kim B. A recombinant adenovirus bicistronically expressing porcine interferon- and interferon- enhances antiviral effects against foot-and-mouth disease virus. Antiviral Res 2014, 104, 52-58. DOI |
10 | Kim SM, Park JH, Lee KN, Kim SK, You SH, Kim T, Tark D, Lee HS, Seo MG, Kim B. Robust protection against highly virulent foot-and-mouth disease virus in swine by combination treatment with recombinant adenoviruses expressing porcine alpha and gamma interferons and multiple small interfering RNAs. J Virol 2015, 89, 8267-8279. DOI |
11 | Knowles NJ, Samuel AR. Molecular epidemiology of foot-and-mouth disease virus. Virus Res 2003, 91, 65-80. DOI |
12 | Lee DU, Je SH, Yoo SJ, Kwon T, Shin JY, Byun JJ, Park JH, Jeong KW, Ku JM, Lyoo YS. Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. J Vet Pharmacol Ther 2017, 40, 561-568. DOI |
13 | Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop NE Jr. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991, 50, 442-449. DOI |
14 | Moraes MP, Chinsangaram J, Brum MC, Grubman MJ. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 2003, 22, 268-279. DOI |
15 | Park JN, Ko MK, Kim RH, Park ME, Lee SY, Yoon JE, Choi JH, You SH, Park JW, Lee KN, Chun JE, Kim SM, Tark D, Lee HS, Ko YJ, Kim B, Lee MH, Park JH. Construction of stabilized and tagged foot-and-mouth disease virus. J Virol Methods 2016, 237, 187-191. DOI |
16 | Grubman MJ. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33, 227-234. DOI |
17 | Moraes MP, de Los Santos T, Koster M, Turecek T, Wang H, Andreyev VG, Grubman MJ. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J Virol 2007, 81, 7124-7135. DOI |
18 | Mort M, Convey I, Baxter J, Bailey C. Animal disease and human trauma: the psychosocial implications of the 2001 UK foot and mouth disease disaster. J Appl Anim Welf Sci 2008, 11, 133-148. DOI |
19 | Nettleton PF, Davies MJ, Rweyemamu MM. Guanidine and heat sensitivity of foot-and-mouth disease virus (FMDV) strains. J Hyg (Lond) 1982, 89, 129-138. DOI |
20 | Paarlberg PL, Lee JG, Seitzinger AH. Potential revenue impact of an outbreak of foot-and-mouth disease in the United States. J Am Vet Med Assoc 2002, 220, 988-992. DOI |
21 | Perales C, Agudo R, Domingo E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 2009, 4, e5554. DOI |
22 | Alexandersen S, Zhang Z, Donaldson AI, Garland AJ. The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol 2003, 129, 1-36. DOI |
23 | Quan M, Murphy CM, Zhang Z, Alexandersen S. Determinants of early foot-and-mouth disease virus dynamics in pigs. J Comp Pathol 2004, 131, 294-307. DOI |
24 | Rada B, Dragun M. Antiviral action and selectivity of 6-azauridine. Ann N Y Acad Sci 1977, 284, 410-417. DOI |
25 | Richmond JY, Hamilton LD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc Natl Acad Sci U S A 1969, 64, 81-86. DOI |
26 | Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003, 311, 339-349. DOI |
27 | Alexandersen S, Donaldson AI. Further studies to quantify the dose of natural aerosols of foot-and-mouth disease virus for pigs. Epidemiol Infect 2002, 128, 313-323. DOI |
28 | Belsham GJ. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog Biophys Mol Biol 1993, 60, 241-260. DOI |
29 | Salazar M, Yun NE, Poussard AL, Smith JN, Smith JK, Kolokoltsova OA, Patterson MJ, Linde J, Paessler S. Effect of ribavirin on junin virus infection in guinea pigs. Zoonoses Public Health 2012, 59, 278-285. DOI |
30 | Sainz B Jr, Halford WP. Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol 2002, 76, 11541-11550. DOI |
31 | Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin Biol Ther 2005, 5, 673-682. DOI |
32 | Vollstedt S, Arnold S, Schwerdel C, Franchini M, Alber G, Di Santo JP, Ackermann M, Suter M. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol 2004, 78, 3846-3850. DOI |
33 | Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D, Yu L. Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol 2014, 88, 4008-4020. DOI |